Jove
Visualize
Contact Us

Related Experiment Videos

MS-325 EPIX.

A E Mahfouz1

  • 1Cairo University, School of Medicine, Cairo, Egypt. mahfouzae@yahoo.com

Current Opinion in Investigational Drugs (London, England : 2000)
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gadolinium-enhanced MR angiography of the breast: is breast cancer associated with ipsilateral higher vascularity?

European radiology·2001
Same author

MRI of intralesional hemolysis in focal nodular hyperplasia of the liver.

Journal of computer assisted tomography·1999
Same author

Comparison of angiography, CT arteriography and MR imaging in assessment of liver metastases treated by percutaneous transcatheter intraarterial chemotherapy.

Liver·1997
Same author

Peripheral washout sign on contrast-enhanced MR images of the breast.

Radiology·1997
Same author

Hepatic magnetic resonance imaging: new techniques and contrast agents.

Endoscopy·1997
Same author

Hyperintense benign liver lesions on spin-echo T1-weighted MR images: pathologic correlations.

Abdominal imaging·1997
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

MS-325, also known as AngioMARK, is a specialized magnetic resonance imaging contrast agent designed to stay in the bloodstream longer than standard agents. By binding to albumin, it improves the clarity of blood vessel imaging, which helps doctors detect conditions like peripheral vascular disease. Researchers are also exploring its potential for monitoring gene therapy effects in muscular dystrophy models.

Area of Science:

  • Cardiovascular imaging research within MS-325 clinical development
  • Diagnostic radiology and contrast agent pharmacology

Background:

No prior work had resolved how to extend the intravascular residence time of magnetic resonance contrast agents effectively. Standard gadolinium-based agents typically clear from the circulation too rapidly for high-resolution vascular imaging. That uncertainty drove the development of compounds capable of prolonged blood retention. Prior research has shown that albumin binding can significantly alter the pharmacokinetic profile of imaging tracers. This gap motivated the creation of MS-325, which incorporates specific chemical modifications to interact with serum proteins. It was already known that enhancing magnetic properties requires stabilizing the metal ion within a complex. This research context highlights the necessity for agents that remain within the vasculature during scanning. The current landscape of diagnostic radiology relies on these specialized tools to improve clinical outcomes for patients.

Purpose Of The Study:

The aim of this study is to evaluate the clinical and biophysical properties of MS-325 as an intravascular contrast agent. Researchers sought to address the need for improved imaging of blood vessels and blood flow. This project investigates how the agent interacts with albumin to enhance magnetic resonance signals. The team focused on the potential for detecting aortoiliac occlusive disease in patients with peripheral vascular conditions. Another objective involved assessing the safety and stability profile of the gadolinium-based complex. The study also explores the utility of the agent in monitoring gene therapy effects within muscular dystrophy models. This work intends to provide evidence for the clinical application of the tracer in cardiovascular diagnostics. The motivation stems from the requirement for agents that remain in the circulation longer than traditional contrast media.

Keywords:
gadolinium complexalbumin bindingvascular imagingcontrast agent pharmacology

Frequently Asked Questions

The researchers propose that MS-325 binds reversibly to albumin, which retains the agent in the bloodstream. This interaction triggers a biophysical phenomenon that increases the magnetic properties of the gadolinium ion by approximately ten-fold compared to unbound states.

MS-325 is a stable complex consisting of a gadolinium ion paired with an organic chelating agent. It features novel chemical groups that facilitate its temporary attachment to serum albumin, distinguishing it from standard contrast agents.

The agent requires reversible albumin binding to remain within the vasculature during the imaging procedure. Without this interaction, the compound would likely clear from the blood too quickly to provide the sustained signal enhancement needed for detailed vascular visualization.

Related Experiment Videos

Main Methods:

Review approach involved evaluating the chemical stability and safety profile of the gadolinium-based complex. Investigators assessed the biophysical interactions between the novel chemical groups and serum albumin. The team examined the pharmacokinetic behavior of the agent to determine its intravascular retention time. Researchers utilized mouse models to test the efficacy of the compound in monitoring gene therapy outcomes. The approach included comparing the properties of this agent against currently approved clinical contrast tracers. Scientists analyzed the magnetic signal enhancement resulting from the reversible protein binding mechanism. The study design focused on validating the agent for detecting vascular occlusions in patients with peripheral disease. Investigators synthesized data regarding the elimination profile to ensure patient safety during diagnostic procedures.

Main Results:

Key findings from the literature demonstrate that MS-325 enhances the magnetic properties of the gadolinium ion approximately ten-fold. The agent achieves this through a reversible binding interaction with albumin that retains it within the blood. Data indicate that the compound maintains a stable and safe profile similar to other approved clinical agents. Results show that the agent effectively demonstrates the presence of microscopic muscular dystrophy in animal models. The literature confirms its utility in monitoring the effects of gene therapy in these specific disease models. Findings support the application of the agent for imaging blood vessels in patients with peripheral vascular disease. The evidence highlights its capacity to detect aortoiliac occlusive disease in clinical trials. Observations confirm that the agent possesses a favorable elimination profile for diagnostic use.

Conclusions:

The authors suggest that MS-325 offers a stable and safe profile comparable to existing clinical agents. Synthesis and implications indicate that reversible albumin binding provides a distinct mechanism for intravascular retention. Researchers propose that this interaction enhances the magnetic properties of the gadolinium ion by approximately ten-fold. The data support the utility of this agent for detecting aortoiliac occlusive disease in clinical settings. Evidence also points toward potential applications in monitoring gene therapy effects within muscular dystrophy models. The study implies that the chemical structure allows for effective imaging of blood flow and vascular anatomy. These findings confirm that the agent maintains a favorable elimination profile despite its unique binding characteristics. The work provides a basis for future diagnostic applications in patients with cardiovascular conditions.

The study utilizes this agent as a tool to monitor the physiological effects of gene therapy in a mouse model of muscular dystrophy. It serves as a marker to demonstrate the presence of microscopic disease changes.

The researchers measured the magnetic properties of the gadolinium ion when bound to albumin. They observed a ten-fold increase in signal enhancement, which is the key phenomenon enabling high-quality imaging of blood vessels and flow.

The authors propose that this agent is suitable for the detection of aortoiliac occlusive disease. They suggest that its stability and safety profile make it a viable candidate for clinical applications in patients with peripheral vascular disease.